MA47121A - Molécules de liaison pour le traitement du cancer - Google Patents

Molécules de liaison pour le traitement du cancer

Info

Publication number
MA47121A
MA47121A MA047121A MA47121A MA47121A MA 47121 A MA47121 A MA 47121A MA 047121 A MA047121 A MA 047121A MA 47121 A MA47121 A MA 47121A MA 47121 A MA47121 A MA 47121A
Authority
MA
Morocco
Prior art keywords
binding molecules
cancer treatment
cancer
treatment
molecules
Prior art date
Application number
MA047121A
Other languages
English (en)
French (fr)
Inventor
Ertan Eryilmaz
Timothy Fenn
Rajkumar Ganesan
Juan Manuel Garcia-Martinez
Jason Ho
Christian Koessl
Klaus-Peter Kuenkele
Saurabh Sen
Abdulsalam Shaaban
Vladimir Voynov
Andreas Wernitznig
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA47121A publication Critical patent/MA47121A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA047121A 2016-12-22 2017-12-21 Molécules de liaison pour le traitement du cancer MA47121A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437770P 2016-12-22 2016-12-22
EP17155973.5A EP3360898A1 (de) 2017-02-14 2017-02-14 Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs

Publications (1)

Publication Number Publication Date
MA47121A true MA47121A (fr) 2019-10-30

Family

ID=58043942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047121A MA47121A (fr) 2016-12-22 2017-12-21 Molécules de liaison pour le traitement du cancer

Country Status (15)

Country Link
US (2) US10858438B2 (de)
EP (2) EP3360898A1 (de)
JP (1) JP7196076B2 (de)
KR (1) KR102651761B1 (de)
CN (1) CN110582513B (de)
AU (1) AU2017384687B2 (de)
BR (1) BR112019011750A2 (de)
CA (1) CA3046591A1 (de)
CO (1) CO2019006320A2 (de)
EA (1) EA201991480A1 (de)
MA (1) MA47121A (de)
MX (1) MX391650B (de)
PE (1) PE20191251A1 (de)
TW (1) TWI790219B (de)
WO (1) WO2018115231A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
US20210115152A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Composition of bispecific antibodies and method of use thereof
EP3725370A1 (de) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modifizierte anti-pd-l1-antikörper und verfahren und verwendungen zur behandlung einer neurodegenerativen erkrankung
JP2023526223A (ja) * 2020-05-11 2023-06-21 クリーブ セラピューティクス，インク． がん処置のためのＶＣＰ／ｐ９７阻害薬
WO2021236658A1 (en) * 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
BR112023015561A2 (pt) 2021-02-03 2023-11-14 Univ Minnesota Compostos imunoestimuiladores e conjugados
WO2022261136A1 (en) * 2021-06-07 2022-12-15 Flagship Pioneering Innovations Vii, Llc Compositions and methods for targeted delivery of therapeutic agents
CN113512117B (zh) * 2021-07-12 2023-08-22 武汉麦考津生物科技有限公司 一种可结合cd206的抗体及其应用
US20250270314A1 (en) * 2021-08-02 2025-08-28 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
WO2023023677A1 (en) * 2021-08-20 2023-02-23 University Of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
EP4518905A1 (de) 2022-05-06 2025-03-12 Seagen Inc. Immunmodulatorische antikörper-wirkstoff-konjugate
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
JP2025525904A (ja) 2022-08-03 2025-08-07 シージェン インコーポレイテッド 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
EP4601696A1 (de) * 2022-10-14 2025-08-20 Flagship Pioneering Innovations VII, LLC Zusammensetzungen und verfahren zur gezielten freisetzung von therapeutika
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用
EP4615874A1 (de) 2022-11-10 2025-09-17 Immuvia Inc Zytotoxische bispezifische antikörper mit bindung an dr5 und muc16 und verwendungen davon
CN120712286A (zh) 2023-02-23 2025-09-26 翰森生物有限责任公司 抗体、抗原结合片段和使用方法
AU2024350163A1 (en) * 2023-09-25 2026-04-02 Trio Pharmaceuticals, Inc. Targeted activation of endogenous cell death
WO2025108446A1 (en) * 2023-11-23 2025-05-30 LaNova Medicines Limited Anti-cdh17 antibodies and conjugates thereof
WO2025242099A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体偶联药物及其用途
WO2025261505A1 (zh) * 2024-06-21 2025-12-26 映恩生物制药（苏州）有限公司 一种抗cdh17的抗体药物偶联物及其应用
US20260078179A1 (en) 2024-07-18 2026-03-19 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof
WO2026017120A1 (zh) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 抗cdh17/egfr/cd16a三特异性抗体及其用途
WO2026046327A1 (en) * 2024-08-29 2026-03-05 Utc Therapeutics (Shanghai) Co., Ltd. Cdh17 targetting antibodies, chimeric antigen receptors, and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (de) 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (de) 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP0979102A4 (de) 1997-04-30 2005-11-23 Enzon Inc Einzelsträngige polypeptide modifiziert durch polyalkylenoxid
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
EP1456410A2 (de) 2001-12-11 2004-09-15 AlgoNomics N.V. Vefahren für die ausstellung von loops aus immunogloblin-domänen
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
CA2773515C (en) * 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
US20130259878A1 (en) * 2010-10-20 2013-10-03 Oxford Biotherapeutics Ltd Antibodies
US20130025987A1 (en) 2011-07-18 2013-01-31 David Batterbee Methods and apparatus for controlling a fluid damper
EP2684896A1 (de) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
NO2776305T3 (de) 2014-04-23 2018-01-27
MA40513A (fr) 2014-08-12 2017-06-21 Novartis Ag Conjugués médicament-anticorps anti-cdh6
TW201625692A (zh) 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
IL308212A (en) * 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
RS61510B1 (sr) 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs

Also Published As

Publication number Publication date
AU2017384687A1 (en) 2019-06-13
CO2019006320A2 (es) 2019-06-28
MX391650B (es) 2025-03-21
US11851495B2 (en) 2023-12-26
US20210095038A1 (en) 2021-04-01
US10858438B2 (en) 2020-12-08
EP3559040A2 (de) 2019-10-30
AU2017384687B2 (en) 2025-01-23
MX2019007511A (es) 2019-09-04
TWI790219B (zh) 2023-01-21
CN110582513A (zh) 2019-12-17
JP2020501586A (ja) 2020-01-23
KR102651761B1 (ko) 2024-03-26
PE20191251A1 (es) 2019-09-18
WO2018115231A3 (en) 2018-08-02
BR112019011750A2 (pt) 2019-10-29
EP3360898A1 (de) 2018-08-15
KR20190099223A (ko) 2019-08-26
US20180179287A1 (en) 2018-06-28
CA3046591A1 (en) 2018-06-28
EA201991480A1 (ru) 2020-01-15
TW201835102A (zh) 2018-10-01
JP7196076B2 (ja) 2022-12-26
EP3559040B1 (de) 2026-04-08
WO2018115231A2 (en) 2018-06-28
CN110582513B (zh) 2023-11-14

Similar Documents

Publication Publication Date Title
MA47121A (fr) Molécules de liaison pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3621592A4 (de) Kombinationstherapien zur behandlung von krebs
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3285773A4 (de) Kombinationstherapie zur behandlung von krebs
EP3397963A4 (de) P38-mapk-hemmung zur behandlung von krebs
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3452060A4 (de) Kombinationstherapie für krebsbehandlung
EP3436002A4 (de) Pharmazeutische kombinationen zur behandlung von krebs
EP3389645A4 (de) Kombinationen zur behandlung von krebs
MA45429A (fr) Polythérapie pour le traitement du cancer
EP3351189A4 (de) Endoskopbehandlungsinstrument
EP3359255A4 (de) Kombinationstherapien zur behandlung von krebs
EP3400010A4 (de) Anti-her2-kombinationen zur behandlung von tumoren
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3490561A4 (de) Kombinationen zur behandlung von krebs
EP3400011A4 (de) Anti-cd20-kombinationen zur behandlung von tumoren
EP3383407A4 (de) Cytarabinkonjugate zur krebstherapie
EP3630196A4 (de) Kombinationstherapien zur behandlung von krebs
EP3331510A4 (de) Kombinationstherapien zur behandlung von krebs
EP3335041A4 (de) Biomarker zur behandlung von alopecia areata
MA41123A (fr) Polythérapie pour le traitement du cancer